Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-05-16

Clinical Trial Update: Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating KRYSTEXXA (pegloticase) plus methotrexate in uncontrolled gout has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KRYSTEXXA (pegloticase)
  • METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Amgen | Conditions: Gout | Phase 4 | Status: COMPLETED | Results posted: 2022-05-16